NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
Winther, S B, Skuladottir, H, Hofsli, E, Shah, C-H, Yilmaz, M K, Österlund, P J, Berglund, Å, Glimelius, B, Qvortrup, C, Sorbye, H, Pfeiffer, P
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
617PEarly response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Qvortrup, C, Yilmaz, M, Möller, S, Zitnjak, D, Maltha, L, Krogh, M, Petersen, L Noergaard, Hejlesen, F, Winther, S B, Thomsen, K G, Pfeiffer, P
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
455PDNORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
Winther, S B, Skuladottir, H, Hofsli, E, Shah, C-H, Yilmaz, M K, Österlund, P J, Berglund, Å, Glimelius, B, Qvortrup, C, Sorbye, H, Pfeiffer, P
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)
Winther, S.B., Østerlund, P., Berglund, Å, Glimelius, B., Qvortrup, C., Sorbye, H., Pfeiffer, P.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study
Liposits, Gabor, Winther, Stine B., Ryg, Jesper, Skuladottir, Halla, Möller, Sören, Hofsli, Eva, Shah, Carl-Henrik, Poulsen, Laurids Østergaard, Berglund, Åke, Qvortrup, Camilla, Osterlund, Pia, Glimelius, Bengt, Sorbye, Halfdan, Pfeiffer, Per
Published in Journal of geriatric oncology (01.03.2024)
Published in Journal of geriatric oncology (01.03.2024)
Get full text
Journal Article
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study
Liposits, Gabor, Ryg, Jesper, Skuladottir, Halla, Winther, Stine B., Möller, Sören, Hofsli, Eva, Shah, Carl-Henrik, Poulsen, Laurids Østergaard, Berglund, Åke, Qvortrup, Camilla, Osterlund, Pia, Glimelius, Bengt, Sorbye, Halfdan, Pfeiffer, Per
Published in Journal of geriatric oncology (01.01.2023)
Published in Journal of geriatric oncology (01.01.2023)
Get full text
Journal Article
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
Liposits, Gabor, Eshøj, Henrik Rode, Möller, Sören, Winther, Stine Brændegaard, Skuladottir, Halla, Ryg, Jesper, Hofsli, Eva, Shah, Carl-Henrik, Poulsen, Laurids Østergaard, Berglund, Åke, Qvortrup, Camilla, Österlund, Pia, Glimelius, Bengt, Sorbye, Halfdan, Pfeiffer, Per
Published in Cancers (26.05.2021)
Published in Cancers (26.05.2021)
Get full text
Journal Article
Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
Liposits, G, Ryg, J, Skuladottir, H, Winther, SB, Moller, S, Hofsli, E, Shah, CH, Oestergaard, LP, Berglund, A, Qvortrup, C, Osterlund, PJ, Glimelius, B, Sorbye, H, Pfeiffer, P
Published in ANNALS OF ONCOLOGY (2022)
Published in ANNALS OF ONCOLOGY (2022)
Get full text
Conference Proceeding
The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
Liposits, G, Skuladottir, H, Ryg, J, Winther, SB, Moller, S, Hofsli, E, Shah, CH, Oestergaard, LP, Berglund, A, Qvortrup, C, Osterlund, PJ, Johansen, JS, Glimelius, B, Sorbye, H, Pfeiffer, P
Published in ANNALS OF ONCOLOGY (2022)
Published in ANNALS OF ONCOLOGY (2022)
Get full text
Conference Proceeding
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study
Liposits, Gabor, Skuladottir, Halla, Ryg, Jesper, Winther, Stine Brændegaard, Möller, Sören, Hofsli, Eva, Shah, Carl-Henrik, Poulsen, Laurids Østergaard, Berglund, Åke, Qvortrup, Camilla, Osterlund, Pia, Johansen, Julia S, Glimelius, Bengt, Sorbye, Halfdan, Pfeiffer, Per
Published in Journal of clinical medicine (23.09.2022)
Published in Journal of clinical medicine (23.09.2022)
Get full text
Journal Article